News | Heart Failure | October 27, 2021

FDA Revises Impulse Dynamics Optimizer Smart Device Labeling Opening it to More Patients

Change removes requirement for normal sinus rhythm


October 27, 2021 — Impulse Dynamics announced the U.S. Food and Drug Administration approved a modification of labeling for the Optimizer Smart medical device, allowing the removal of “normal sinus rhythm” (NSR) from the indications for use statement. Since heart failure patients are no longer required to be in NSR at the time of Optimizer implant, heart rhythm does not impose any restrictions on patients eligible for Optimizer implant, thereby vastly increasing the number of patients who can be treated with CCM therapy.

“We applaud the FDA’s decision based on clinical evidence provided to remove the previous barrier to CCM therapy concerned with heart rhythm, opening it up to additional patients in need,” said Jason Spees, president and chief commercial officer of Impulse Dynamics. “This decision removes what had been a significant barrier for efficient and effective clinical decision making in the best interest of hundreds of thousands of patients.” Impulse Dynamics estimates the current addressable market for CCM therapy in the U.S. alone to be over 1.1 million patients.[1]

Since introducing the two-lead configuration of the Optimizer Smart in 2019, the device’s design has been capable of supporting patients with heart rhythms other than NSR; however, the inclusion of such patients has been prohibited by the approved labeling in the U.S. until today. In the EU, patients not in NSR, including those with atrial fibrillation (A-fib), have been widely treated with CCM therapy with excellent outcomes since 2016.

Additionally, the FDA’s decision was based on the submission of data from a long-term clinical study led by Dr. Jürgen Kuschyk in 2021.[2] The study, comprised of a registry featuring 503 patients in the EU, compared the outcomes of those with A-fib treated with CCM therapy to a cohort treated with CCM that did not have A-fib. Both groups exhibited positive results, and no safety issues related to heart rhythm were identified. Today’s announcement of FDA approval of a simple modification of the labeling to remove “NSR” from the Optimizer’s indications for use has significantly expanded the market for CCM therapy to patients with many different heart rhythms, including A-fib.

“CCM is an important therapeutic option appropriate for patients who manifest lifestyle limiting symptoms despite guideline-directed medical therapy (GDMT) for congestive heart failure (CHF)," said George Mark, M.D., FACC, a clinical cardiac electrophysiologist with The Heart House in Marlton, N.J. "Many of these same patients also suffer from atrial arrhythmias like atrial fibrillation and flutter, which has, up until now, prevented the timely use of CCM. Access to CCM therapy would often be delayed to assess atrial fibrillation burden further, provide opportunities to restore sinus rhythm or titrate medication. Previously, the presence of A-fib presented, at the very least, a mental barrier for clinicians and sometimes eliminated CCM from consideration. This welcomed change to the labeling will simplify the process of assessing suitable candidates for CCM therapy, and for many, will shorten the amount of time required to receive treatment.”

References:

1. This estimate is based on the current CCM therapy indications, which include patients diagnosed with NYHA Class III HF, who remain symptomatic despite guideline-directed medical therapy, and who are not indicated for cardiac resynchronization therapy.

2. Jürgen Kuschyk, Peter Falk, Thomas Demming, et al. Long-term clinical experience with cardiac contractility modulation therapy delivered by the Optimizer Smart system. European Journal of Heart Failure. First published 17 May 2021. doi.org/10.1002/ejhf.2202
 

Related Content

News | Heart Failure

November 19, 2021 — Adults treated with empagliflozin during hospitalization for acute heart failure experienced a ...

Home November 19, 2021
Home
News | Heart Failure

November 17, 2021 — Canagliflozin, a medication used to treat type 2 diabetes, was found to greatly improve symptoms and ...

Home November 17, 2021
Home
News | Heart Failure

November 10, 2021 — Ancora Heart Inc., a company developing a novel therapy to address heart failure, announced results ...

Home November 10, 2021
Home
News | Heart Failure

November 2, 2021 — Cardionomic Inc. announce initial U.S. enrollment in its global Cardiac Pulmonary Nerve Stimulation ...

Home November 02, 2021
Home
News | Heart Failure

October 1, 2021 — A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in ...

Home October 04, 2021
Home
News | Heart Failure

September 28, 2021 — Hemodynamic guided management using the CardioMEMS device may reduce heart failure hospitalizations ...

Home September 28, 2021
Home
News | Heart Failure

September 22, 2021 — A cardiothoracic surgical team with University of Louisville Health – Jewish Hospital has performed ...

Home September 22, 2021
Home
News | Heart Failure

September 21, 2021 — The European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and ...

Home September 21, 2021
Home
News | Heart Failure

June 15, 2021 — VoluMetrix, a Nashville-based biotech startup dedicated to creating a new wave of solutions for vital ...

Home June 15, 2021
Home
News | Heart Failure

June 7, 2021 – Cardiologists at Henry Ford Hospital are first in the U.S. and second in the world to implant a ...

Home June 07, 2021
Home
Subscribe Now